DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

Market Cap	734.61B
Revenue (ttm)	894.93B
Net Income (ttm)	60.50B
Shares Out	44.74M
EPS (ttm)	1,358.99
PE Ratio	12.08
Forward PE	9.45
Dividend	200.00 (1.21%)
Ex-Dividend Date	Dec 27, 2024

Volume	124,886
Average Volume	171,298
Open	16,490
Previous Close	16,530
Day's Range	16,410 - 16,520
52-Week Range	14,400 - 20,450
Beta	0.20
RSI	28.84
Earnings Date	Mar 11, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 1,233
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086450

Financial Performance

In 2024, DongKook Pharmaceutical's revenue was 812.17 billion, an increase of 11.10% compared to the previous year's 730.99 billion. Earnings were 60.77 billion, an increase of 29.92%.